The Latest Cardiac and Vascular News
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient in their multicenter Phase 2 trial assessing efficacy and safety of CDR132L in 280 […]
First-in-class compound showed excellent tolerability and safety Unique mode of action in chronic heart failure confirmed by data on cardiac function and biomarkers Phase II studies in subacute and chronic heart failure planned Hanover, Germany, November 12, 2020 – Cardior Pharmaceuticals GmbH, […]
